Astrazeneca Ab

Astra Aktiebolag

Astra Ab

Rspr Pharma Ab

Ltb4 Sweden Ab

Karol Horvath

Martin Hans Bohlin

Tord Bertil Inghardt

Martin Viertelhaus

Anett Perlberg

Maria Boije

Rune Sandberg

Ulf Larsson

Bo Lindqvist

Ulrika Rosenström

There is provided a hemihydrate form of the sodium salt of pemirolast.

Crystalline form of pemirolast

Leukotriene B, 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B(LTB) are known in the art. The present inventors have discovered a crystal form of LTBand the present invention therefore relates to crystal forms of LTBin general, and the novel crystal form A of LTBin particular.

[object Object]

The present invention relates to a novel crystalline form of the compound (S)-2-ethoxy-3-&lsqb;4-(2-&lcub;4-methanesulfonyloxyphenyl&rcub;ethoxy)phenyl&rsqb;propanoic acid, shown by formula (I), or a pharmaceutically-acceptable salt thereof, and solvates thereof. The invention also concerns methods of treating one or more metabolic disease conditions, particularly those associated with Insulin Resistance Syndrome, and the use of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof, as active ingredient, as well as processes for the manufacture of a crystalline form of the compound, or a pharmaceutically-acceptable salt thereof, or a solvate thereof.

Crytalline form of (s)-2 ethoxy -3-&lsqb;4-(2-&lcub;4- methanesulfonyloxyphenyl&rcub; ethoxy)phenyl&rsqb;propanoic acid

A process for producing spherical agglomerates of inogatran having a narrow size distribution, and the compound inogatran anhydrate.

Production of agglomerates of inogatran and the compound inogatran anhydrate

The present invention relates to a novel monophosphate salt of isopropyl-methyl-&lsqb;2-(3-n-propoxyphenoxy)ethyl&rsqb;amine. Moreover, the present invention also relates to a process for the preparation of the monophosphate salt of isopropyl-methyl-&lsqb;2-(3-n-propoxyphenoxy)ethyl&rsqb;amine as well as a pharmaceutical formulation containing it and its use in medicine.

Phosphate salt of isopropyl-methyl- &lsqb;2-(3-n-propoxyphenoxy)ethyl&rsqb;amine

Crystalline form of the S-enantiomer of omeprazole

Polymorphic compounds

Growing community of inventors

Södertälje, Sweden

Karol Horvath